271 related articles for article (PubMed ID: 35535491)
21. Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia.
He C; Peng Z; Zhang D; Guo Y; Liang T; Zhao Y; Yu L; Zhang Q; Chang Z; Xiao Y; Li N; Xue H; Wu S; Zhao ZJ; Zhang C; Chen Y
Biochem Pharmacol; 2023 Jul; 213():115588. PubMed ID: 37187274
[TBL] [Abstract][Full Text] [Related]
22. Mutations in RIT1 cause Noonan syndrome with possible juvenile myelomonocytic leukemia but are not involved in acute lymphoblastic leukemia.
Cavé H; Caye A; Ghedira N; Capri Y; Pouvreau N; Fillot N; Trimouille A; Vignal C; Fenneteau O; Alembik Y; Alessandri JL; Blanchet P; Boute O; Bouvagnet P; David A; Dieux Coeslier A; Doray B; Dulac O; Drouin-Garraud V; Gérard M; Héron D; Isidor B; Lacombe D; Lyonnet S; Perrin L; Rio M; Roume J; Sauvion S; Toutain A; Vincent-Delorme C; Willems M; Baumann C; Verloes A
Eur J Hum Genet; 2016 Aug; 24(8):1124-31. PubMed ID: 26757980
[TBL] [Abstract][Full Text] [Related]
23. SHP2 sails from physiology to pathology.
Tajan M; de Rocca Serra A; Valet P; Edouard T; Yart A
Eur J Med Genet; 2015 Oct; 58(10):509-25. PubMed ID: 26341048
[TBL] [Abstract][Full Text] [Related]
24. Germline mutation of CBL is associated with moyamoya disease in a child with juvenile myelomonocytic leukemia and Noonan syndrome-like disorder.
Hyakuna N; Muramatsu H; Higa T; Chinen Y; Wang X; Kojima S
Pediatr Blood Cancer; 2015 Mar; 62(3):542-4. PubMed ID: 25283271
[TBL] [Abstract][Full Text] [Related]
25. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.
Kratz CP; Niemeyer CM; Castleberry RP; Cetin M; Bergsträsser E; Emanuel PD; Hasle H; Kardos G; Klein C; Kojima S; Stary J; Trebo M; Zecca M; Gelb BD; Tartaglia M; Loh ML
Blood; 2005 Sep; 106(6):2183-5. PubMed ID: 15928039
[TBL] [Abstract][Full Text] [Related]
26. Use of human androgen receptor gene analysis to aid the diagnosis of JMML in female noonan syndrome patients.
Lavin VA; Hamid R; Patterson J; Alford C; Ho R; Yang E
Pediatr Blood Cancer; 2008 Aug; 51(2):298-302. PubMed ID: 18454468
[TBL] [Abstract][Full Text] [Related]
27. Modeling (not so) rare developmental disorders associated with mutations in the protein-tyrosine phosphatase SHP2.
Solman M; Woutersen DTJ; den Hertog J
Front Cell Dev Biol; 2022; 10():1046415. PubMed ID: 36407105
[TBL] [Abstract][Full Text] [Related]
28. Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.
De Rocca Serra-Nédélec A; Edouard T; Tréguer K; Tajan M; Araki T; Dance M; Mus M; Montagner A; Tauber M; Salles JP; Valet P; Neel BG; Raynal P; Yart A
Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4257-62. PubMed ID: 22371576
[TBL] [Abstract][Full Text] [Related]
29. Noonan Syndrome-related Myeloproliferative Disorder Occurring in the Neonatal Period: Case Report and Literature Review.
Hoshino Y; Moriya K; Mitsui-Sekinaka K; Hashimoto Y; Nakayama S; Sajiki D; Muramatsu H; Hagiwara H; Suzuki S; Sekinaka Y; Wakamatsu H; Kawaguchi H; Imai K
J Pediatr Hematol Oncol; 2024 Mar; 46(2):e176-e179. PubMed ID: 38132703
[TBL] [Abstract][Full Text] [Related]
30. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
[TBL] [Abstract][Full Text] [Related]
31. Constitutional NRAS mutations are rare among patients with Noonan syndrome or juvenile myelomonocytic leukemia.
Kraoua L; Journel H; Bonnet P; Amiel J; Pouvreau N; Baumann C; Verloes A; Cavé H
Am J Med Genet A; 2012 Oct; 158A(10):2407-11. PubMed ID: 22887781
[TBL] [Abstract][Full Text] [Related]
32. The tyrosine phosphatase Shp2 in development and cancer.
Grossmann KS; Rosário M; Birchmeier C; Birchmeier W
Adv Cancer Res; 2010; 106():53-89. PubMed ID: 20399956
[TBL] [Abstract][Full Text] [Related]
33. PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice.
Paardekooper Overman J; Yi JS; Bonetti M; Soulsby M; Preisinger C; Stokes MP; Hui L; Silva JC; Overvoorde J; Giansanti P; Heck AJ; Kontaridis MI; den Hertog J; Bennett AM
Mol Cell Biol; 2014 Aug; 34(15):2874-89. PubMed ID: 24865967
[TBL] [Abstract][Full Text] [Related]
34. K-RasV14I recapitulates Noonan syndrome in mice.
Hernández-Porras I; Fabbiano S; Schuhmacher AJ; Aicher A; Cañamero M; Cámara JA; Cussó L; Desco M; Heeschen C; Mulero F; Bustelo XR; Guerra C; Barbacid M
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16395-400. PubMed ID: 25359213
[TBL] [Abstract][Full Text] [Related]
35. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
Niemeyer CM; Flotho C
Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
[TBL] [Abstract][Full Text] [Related]
36. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
Locatelli F; Algeri M; Merli P; Strocchio L
Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
[TBL] [Abstract][Full Text] [Related]
37. After 95 years, it's time to eRASe JMML.
Meynier S; Rieux-Laucat F
Blood Rev; 2020 Sep; 43():100652. PubMed ID: 31980238
[TBL] [Abstract][Full Text] [Related]
38. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
Araki T; Mohi MG; Ismat FA; Bronson RT; Williams IR; Kutok JL; Yang W; Pao LI; Gilliland DG; Epstein JA; Neel BG
Nat Med; 2004 Aug; 10(8):849-57. PubMed ID: 15273746
[TBL] [Abstract][Full Text] [Related]
39. Noonan syndrome-associated SHP2 mutation differentially modulates the expression of postsynaptic receptors according to developmental maturation.
Oh JY; Rhee S; Silva AJ; Lee YS; Kim HK
Neurosci Lett; 2017 May; 649():41-47. PubMed ID: 28366775
[TBL] [Abstract][Full Text] [Related]
40. Transient juvenile myelomonocytic leukemia in the setting of PTPN11 mutation and Noonan syndrome with secondary development of monosomy 7.
O'Halloran K; Ritchey AK; Djokic M; Friehling E
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28084675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
